The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 12, 2021

Filed:

Mar. 08, 2019
Applicant:

Rubius Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Thomas Joseph Wickham, Groton, MA (US);

Sivan Elloul, Newton, MA (US);

Assignee:

Rubius Therapeutics, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 35/18 (2015.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/30 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 35/18 (2013.01); A61K 38/1774 (2013.01); A61K 38/191 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 38/30 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C12N 5/0641 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); A61K 39/39533 (2013.01); A61K 47/6811 (2017.08); C07K 2319/00 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell. The engineered enucleated cells of the present disclosure are useful in methods of activating NK cells and/or CD8+T-cells in a subject in need thereof, such as subjects having cancer or an infectious disease, and in particular cancers or infectious diseases characterized by downregulation of MHC Class I presentation.


Find Patent Forward Citations

Loading…